title: [Clinical and angiographic outcome in patients undergoing elective bare- metal stenting or drug-eluting stenting for total occlusion lesion].
abstract: OBJECTIVE
  To compare the clinical and angiographic outcome in patients with total occlusion lesion treated with drug-eluting stent (DES) or bare-metal stent (BMS).
  
  
  METHODS
  A total of 155 (138 males) consecutive patients with total occlusion lesion underwent successful revascularization with DES (n = 74) or BMS (n = 81) in our hospital were included in this study. All patients received aspirin 300 mg and clopidogrel 75 mg once daily for at least 3 months after the procedure. Clinical and angiographic follow-up were completed in all patients at 6 months post stenting.
  
  
  RESULTS
  Demographic data between the two groups were similar except there was more diabetic patients in DES group (33.8% vs. 18.5%, P < 0.05). A total of 232 stents for 159 target lesions (77 treated with DES, 82 treated with BMS) were implanted. There were 85.4% C ACC/AHA type lesions and 17.0% lesions were treated with overlapping stents. Six months post stenting, the incidence of restenosis (15.6% vs. 41.5%, P < 0.001), the cumulative rate of major adverse cardiac events (MACE) (1.4% vs. 11.1%, P = 0.032) and TLR (5.8% vs. 19.9%, P = 0.001) were significantly lower in DES group than that of BMS group. The incidence of local restenosis in DES group is higher in DES group than that in BMS group (58.3%, 17.6%, P < 0.001). Two DES treated patients developed late in-stent thrombosis.
  
  
  CONCLUSIONS
  For patients with total occlusion lesion, the clinical and angiographic outcome 6 months post DES stenting is clearly superior to that of BMS stenting.
authors.affiliation: Coronary Heart Disease Center, Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. qiaosb1@yahoo.com
authors.forename: Shu-bin
authors.initials: SB
authors.lastname: Qiao
authors.forename: Qing
authors.initials: Q
authors.lastname: Hou
authors.forename: Bo
authors.initials: B
authors.lastname: Xu
authors.forename: Jue
authors.initials: J
authors.lastname: Chen
authors.forename: Hai-bo
authors.initials: HB
authors.lastname: Liu
authors.forename: Yue-jin
authors.initials: YJ
authors.lastname: Yang
authors.forename: Yong-jian
authors.initials: YJ
authors.lastname: Wu
authors.forename: Jin-qing
authors.initials: JQ
authors.lastname: Yuan
authors.forename: Yuan
authors.initials: Y
authors.lastname: Wu
authors.forename: Jun
authors.initials: J
authors.lastname: Dai
authors.forename: Shi-jie
authors.initials: SJ
authors.lastname: You
authors.forename: Wei-hua
authors.initials: WH
authors.lastname: Ma
authors.forename: Pei
authors.initials: P
authors.lastname: Zhang
authors.forename: Zhan
authors.initials: Z
authors.lastname: Gao
authors.forename: Ke-fei
authors.initials: KF
authors.lastname: Dou
authors.forename: Hong
authors.initials: H
authors.lastname: Qiu
authors.forename: Chao-wei
authors.initials: CW
authors.lastname: Mu
authors.forename: Ji-lin
authors.initials: JL
authors.lastname: Chen
authors.forename: Run-lin
authors.initials: RL
authors.lastname: Gao
mesh_terms: D000368:Aged; D017023:Coronary Angiography; D003327:Coronary Disease / Q000150:complications / Q000000981:diagnostic imaging / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000000981:diagnostic imaging; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015607:Stents